Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Yumanity Therapeutics, Inc. (YMTX)
Newly released Crypto mining rig for Yumanity Therapeutics, Inc. coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
2 days ago | GlobeNewsWire
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
3 months ago | GlobeNewsWire
Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
3 months ago | GlobeNewsWire
Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience Conference
3 months ago | GlobeNewsWire
Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
3 months ago | GlobeNewsWire
Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & Development
4 months ago | GlobeNewsWire
Yumanity Therapeutics' Glioblastoma Candidate Shows Efficacy In Animal Studies
4 months ago | Benzinga
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
4 months ago | GlobeNewsWire
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
4 months ago | GlobeNewsWire
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
5 months ago | GlobeNewsWire

About:

Yumanity Therapeutics Inc. discovers and develops disease-modifying therapies for neurodegenerative diseases. It focuses on discovering disease-modifying therapies for patients with Parkinson’s, amyotrophic lateral sclerosis, and Alzheimer’s diseases. The company concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding. Yumanity Therapeutics Inc. has a strategic research collaboration and license agreement with Merck. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Sector:

Healthcare

Industry:

Biotechnology

Address:

Yumanity Therapeutics, Inc. 40 Guest Street Suite 4410 Boston MA 02135 United States

Website:

http://www.yumanity.com

Phone:

617-409-5300

Leave a comment

Your email address will not be published. Required fields are marked *